{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:18:03Z","timestamp":1790295483103,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-1479, Project ID: 441891347"],"award-info":[{"award-number":["SFB-1479, Project ID: 441891347"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["3554\/1-3"],"award-info":[{"award-number":["3554\/1-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-1479, Project ID: 441891347"],"award-info":[{"award-number":["SFB-1479, Project ID: 441891347"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-1479, Project ID: 441891347"],"award-info":[{"award-number":["SFB-1479, Project ID: 441891347"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ruxolitinib is a potent JAK1\/JAK2 inhibitor, approved for the treatment of primary myelofibrosis (PMF) patients based on the concept of inhibition of oncogenic signaling. However, the effect of ruxolitinib on JAK2-V617F allelic burden is modest, suggesting that inhibition of JAK2-V617F signaling-driven clone expansion is not the main mechanism of action. We evaluate whether ruxolitinib mainly blocks the proliferation of the malignant clone or exerts its effects also by targeting non-malignant cells. Therefore, we develop two JAK2-V617F-driven myeloproliferative neoplasm (MPN) mouse models harboring ruxolitinib resistance mutations. Mice carrying ruxolitinib-resistant JAK2-V617F-driven MPN respond to ruxolitinib treatment similar to mice with ruxolitinib-sensitive JAK2-V617F MPN with respect to reduction of spleen size, leukocyte count and pro-inflammatory cytokines in the serum. Ruxolitinib reduces pro-inflammatory cytokines in both stromal cells and non-malignant hematopoietic cells. Using a rigorous ruxolitinib resistance mutation approach, we can prove that ruxolitinib acts independent of oncogenic JAK2-V617F signaling and reduces the main features of MPN disease such as spleen size and leukocyte counts. Our findings characterize the mechanism of action for ruxolitinib in MPN.<\/jats:p>","DOI":"10.1038\/s41467-025-60019-6","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T05:57:51Z","timestamp":1748066271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of JAK1\/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling"],"prefix":"10.1038","volume":"16","author":[{"given":"Sivahari Prasad","family":"Gorantla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstyn Anne","family":"Crossley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Andreas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2560-8488","authenticated-orcid":false,"given":"Teresa","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Khaja Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kleinfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheer Madan Mohan","family":"Gambheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Schaberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-1248","authenticated-orcid":false,"given":"Dominik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0438-7972","authenticated-orcid":false,"given":"Gerin","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonzalez-Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Bentrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Trittler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Rylova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-9481","authenticated-orcid":false,"given":"Geoffroy","family":"Andrieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Quintanilla-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lena","family":"Illert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-8947","authenticated-orcid":false,"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-7753","authenticated-orcid":false,"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"60019_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","volume":"93","author":"E Parganas","year":"1998","unstructured":"Parganas, E. et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385\u2013395 (1998).","journal-title":"Cell"},{"key":"60019_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","volume":"93","author":"H Neubauer","year":"1998","unstructured":"Neubauer, H. et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397\u2013409 (1998).","journal-title":"Cell"},{"key":"60019_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144\u20131148 (2005).","journal-title":"Nature"},{"key":"60019_CR4","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","volume":"106","author":"RL Levine","year":"2005","unstructured":"Levine, R. L. et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106, 3377\u20133379 (2005).","journal-title":"Blood"},{"key":"60019_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054\u20131061 (2005).","journal-title":"Lancet"},{"key":"60019_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779\u20131790 (2005).","journal-title":"N. Engl. J. Med."},{"key":"60019_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387\u2013397 (2005).","journal-title":"Cancer Cell"},{"key":"60019_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma, D. P. et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes. Blood 106, 1207\u20131209 (2005).","journal-title":"Blood"},{"key":"60019_CR9","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal, R. et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123, e123\u2013e133 (2014).","journal-title":"Blood"},{"key":"60019_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi, A. et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 29, 1356\u20131363 (2011).","journal-title":"J. Clin. Oncol."},{"key":"60019_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","volume":"87","author":"R Vaidya","year":"2012","unstructured":"Vaidya, R. et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am. J. Hematol. 87, 1003\u20131005 (2012).","journal-title":"Am. J. Hematol."},{"key":"60019_CR12","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1158\/0008-5472.CAN-10-4002","volume":"71","author":"T Manshouri","year":"2011","unstructured":"Manshouri, T. et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 71, 3831\u20133840 (2011).","journal-title":"Cancer Res."},{"key":"60019_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1006\/cyto.2002.1994","volume":"20","author":"S Hermouet","year":"2002","unstructured":"Hermouet, S. et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine 20, 178\u2013183 (2002).","journal-title":"Cytokine"},{"key":"60019_CR14","doi-asserted-by":"publisher","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","volume":"66","author":"TG Bumm","year":"2006","unstructured":"Bumm, T. G. et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 66, 11156\u201311165 (2006).","journal-title":"Cancer Res."},{"key":"60019_CR15","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s12032-011-0144-1","volume":"29","author":"CC Ponce","year":"2012","unstructured":"Ponce, C. C., de Lourdes, F. C. M., Ihara, S. S. & Silva, M. R. The relationship of the active and latent forms of TGF-beta1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis. Med. Oncol. 29, 2337\u20132344 (2012).","journal-title":"Med. Oncol."},{"key":"60019_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1096\/fj.11-193078","volume":"26","author":"G Hoermann","year":"2012","unstructured":"Hoermann, G. et al. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J. 26, 894\u2013906 (2012).","journal-title":"FASEB J."},{"key":"60019_CR17","doi-asserted-by":"crossref","unstructured":"Verstovsek, S. Therapeutic potential of JAK2 inhibitors. Hematology Am. Soc. Hematol. Educ. Program. 2009, 636\u2013642 (2009).","DOI":"10.1182\/asheducation-2009.1.636"},{"key":"60019_CR18","doi-asserted-by":"crossref","unstructured":"Verstovsek, S. et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1\/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J. Clin. Oncol. 29, 6500 (2011).","DOI":"10.1200\/jco.2011.29.15_suppl.6500"},{"key":"60019_CR19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117\u20131127 (2010).","journal-title":"N. Engl. J. Med."},{"key":"60019_CR20","doi-asserted-by":"crossref","unstructured":"Harrison, C. N. et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J. Clin. Oncol. 29, LBA6501 (2011).","DOI":"10.1200\/jco.2011.29.18_suppl.lba6501"},{"key":"60019_CR21","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama, A. et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109\u20133117 (2010).","journal-title":"Blood"},{"key":"60019_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2011.255","volume":"26","author":"A Deshpande","year":"2012","unstructured":"Deshpande, A. et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 26, 708\u2013715 (2012).","journal-title":"Leukemia"},{"key":"60019_CR23","doi-asserted-by":"publisher","first-page":"e43437","DOI":"10.1371\/journal.pone.0043437","volume":"7","author":"MR Marit","year":"2012","unstructured":"Marit, M. R. et al. Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS ONE 7, e43437 (2012).","journal-title":"PLoS ONE"},{"key":"60019_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep14538","volume":"5","author":"M Kesarwani","year":"2015","unstructured":"Kesarwani, M. et al. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci. Rep. 5, 14538 (2015).","journal-title":"Sci. Rep."},{"key":"60019_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/onc.2010.476","volume":"30","author":"N von Bubnoff","year":"2011","unstructured":"von Bubnoff, N. et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 30, 933\u2013943 (2011).","journal-title":"Oncogene"},{"key":"60019_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1430833","volume":"14","author":"SP Gorantla","year":"2024","unstructured":"Gorantla, S. P. et al. Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms. Front. Oncol. 14, 1430833 (2024).","journal-title":"Front. Oncol."},{"key":"60019_CR27","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1182\/blood-2009-07-236133","volume":"116","author":"SP Gorantla","year":"2010","unstructured":"Gorantla, S. P. et al. Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice. Blood 116, 4600\u20134611 (2010).","journal-title":"Blood"},{"key":"60019_CR28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1126\/science.aac9593","volume":"350","author":"G Gasteiger","year":"2015","unstructured":"Gasteiger, G., Fan, X., Dikiy, S., Lee, S. Y. & Rudensky, A. Y. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350, 981\u2013985 (2015).","journal-title":"Science"},{"key":"60019_CR29","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1634\/stemcells.2006-0548","volume":"25","author":"F Djouad","year":"2007","unstructured":"Djouad, F. et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25, 2025\u20132032 (2007).","journal-title":"Stem Cells"},{"key":"60019_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nm0617-788d","volume":"23","author":"NR West","year":"2017","unstructured":"West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease (vol 23, pg 579, 2017). Nat. Med. 23, 788\u2013788 (2017).","journal-title":"Nat. Med."},{"key":"60019_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"60019_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"60019_CR33","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60019_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173505","volume":"885","author":"M Covington","year":"2020","unstructured":"Covington, M. et al. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases. Eur. J. Pharm. 885, 173505 (2020).","journal-title":"Eur. J. Pharm."},{"key":"60019_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3324\/haematol.2016.151126","volume":"102","author":"JO Mascarenhas","year":"2017","unstructured":"Mascarenhas, J. O. et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica 102, 327\u2013335 (2017).","journal-title":"Haematologica"},{"key":"60019_CR36","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","volume":"18","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas, J. & Hoffman, R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin. Cancer Res. 18, 3008\u20133014 (2012).","journal-title":"Clin. Cancer Res."},{"key":"60019_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/leu.2016.323","volume":"31","author":"CN Harrison","year":"2017","unstructured":"Harrison, C. N. et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 31, 775 (2017).","journal-title":"Leukemia"},{"key":"60019_CR38","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJMc1502524","volume":"372","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch, H. C. & Bjorn, M. E. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 1670 (2015).","journal-title":"N. Engl. J. Med."},{"key":"60019_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","volume":"96","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi, A. M. et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann. Hematol. 96, 1113\u20131120 (2017).","journal-title":"Ann. Hematol."},{"key":"60019_CR40","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser, R. et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29, 2062\u20132068 (2015).","journal-title":"Leukemia"},{"key":"60019_CR41","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","volume":"111","author":"S Xing","year":"2008","unstructured":"Xing, S. et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111, 5109\u20135117 (2008).","journal-title":"Blood"},{"key":"60019_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","volume":"512","author":"L Arranz","year":"2014","unstructured":"Arranz, L. et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512, 78\u201381 (2014).","journal-title":"Nature"},{"key":"60019_CR43","unstructured":"Prestipino, A. et al. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 10, eaam7729 (2018)."},{"key":"60019_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1084\/jem.20111694","volume":"209","author":"O Weigert","year":"2012","unstructured":"Weigert, O. et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J. Exp. Med. 209, 259\u2013273 (2012).","journal-title":"J. Exp. Med"},{"key":"60019_CR45","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","volume":"115","author":"P Koppikar","year":"2010","unstructured":"Koppikar, P. et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115, 2919\u20132927 (2010).","journal-title":"Blood"},{"key":"60019_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe, M. et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 5, 316\u2013331 (2015).","journal-title":"Cancer Discov."},{"key":"60019_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32927-4","volume":"13","author":"S Rai","year":"2022","unstructured":"Rai, S. et al. Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat. Commun. 13, 5346 (2022).","journal-title":"Nat. Commun."},{"key":"60019_CR48","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1158\/1078-0432.CCR-23-0276","volume":"29","author":"J Mascarenhas","year":"2023","unstructured":"Mascarenhas, J. et al. A phase Ib trial of AVID200, a TGF\u03b2 1\/3 trap, in patients with myelofibrosis. Clin. Cancer Res. 29, 3622\u20133632 (2023).","journal-title":"Clin. Cancer Res."},{"key":"60019_CR49","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1158\/0008-5472.CAN-23-3553","volume":"84","author":"D Schmidt","year":"2024","unstructured":"Schmidt, D. et al. Oncogenic calreticulin induces immune escape by stimulating TGF\u03b2 expression and regulatory T-cell expansion in the bone marrow microenvironment. Cancer Res. 84, 2985\u20133003 (2024).","journal-title":"Cancer Res."},{"key":"60019_CR50","doi-asserted-by":"publisher","first-page":"10794","DOI":"10.1158\/0008-5472.CAN-05-0623","volume":"65","author":"MB Nilsson","year":"2005","unstructured":"Nilsson, M. B., Langley, R. R. & Fidler, I. J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 65, 10794\u201310800 (2005).","journal-title":"Cancer Res."},{"key":"60019_CR51","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.bbrc.2006.02.100","volume":"342","author":"JS Yao","year":"2006","unstructured":"Yao, J. S., Zhai, W., Young, W. L. & Yang, G. Y. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem. Biophys. Res. Commun. 342, 1396\u20131404 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"60019_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/sj.jcbfm.9600509","volume":"28","author":"Y Fan","year":"2008","unstructured":"Fan, Y. et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J. Cereb. Blood Flow. Metab. 28, 90\u201398 (2008).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"60019_CR53","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/10428190500054491","volume":"46","author":"JG Kim","year":"2005","unstructured":"Kim, J. G. et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk. Lymphoma 46, 885\u2013891 (2005).","journal-title":"Leuk. Lymphoma"},{"key":"60019_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/(SICI)1099-1069(199812)16:4<143::AID-HON628>3.0.CO;2-U","volume":"16","author":"M Anand","year":"1998","unstructured":"Anand, M., Chodda, S. K., Parikh, P. M. & Nadkarni, J. S. Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis. Hematol. Oncol. 16, 143\u2013154 (1998).","journal-title":"Hematol. Oncol."},{"key":"60019_CR55","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman, A. G. et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 118, 6392\u20136398 (2011).","journal-title":"Blood"},{"key":"60019_CR56","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher, D. A. C. et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling. Leukemia 33, 1978\u20131995 (2019).","journal-title":"Leukemia"},{"key":"60019_CR57","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/sj.leu.2402124","volume":"15","author":"F Di Raimondo","year":"2001","unstructured":"Di Raimondo, F. et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 15, 976\u2013980 (2001).","journal-title":"Leukemia"},{"key":"60019_CR58","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.2830350302","volume":"35","author":"O Katoh","year":"1990","unstructured":"Katoh, O., Kimura, A., Itoh, T. & Kuramoto, A. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am. J. Hematol. 35, 145\u2013150 (1990).","journal-title":"Am. J. Hematol."},{"key":"60019_CR59","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1182\/blood.V88.12.4534.bloodjournal88124534","volume":"88","author":"MC Le Bousse-Kerdiles","year":"1996","unstructured":"Le Bousse-Kerdiles, M. C. et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 88, 4534\u20134546 (1996).","journal-title":"Blood"},{"key":"60019_CR60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0369-8114(00)00021-3","volume":"49","author":"MC Le Bousse-Kerdiles","year":"2001","unstructured":"Le Bousse-Kerdiles, M. C. & Martyre, M. C. French IrnoIM. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol. Biol. 49, 153\u2013157 (2001).","journal-title":"Pathol. Biol."},{"key":"60019_CR61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2141.1997.292671.x","volume":"97","author":"MC Martyre","year":"1997","unstructured":"Martyre, M. C. et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br. J. Haematol. 97, 441\u2013448 (1997).","journal-title":"Br. J. Haematol."},{"key":"60019_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2141.1994.tb04970.x","volume":"88","author":"MC Martyre","year":"1994","unstructured":"Martyre, M. C. et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br. J. Haematol. 88, 9\u201316 (1994).","journal-title":"Br. J. Haematol."},{"key":"60019_CR63","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood.V75.7.1540.1540","volume":"75","author":"T Terui","year":"1990","unstructured":"Terui, T. et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 75, 1540\u20131548 (1990).","journal-title":"Blood"},{"key":"60019_CR64","first-page":"1367","volume":"21","author":"J Thiele","year":"2006","unstructured":"Thiele, J. & Kvasnicka, H. M. Myelofibrosis in chronic myeloproliferative disorders\u2013dynamics and clinical impact. Histol. Histopathol. 21, 1367\u20131378 (2006).","journal-title":"Histol. Histopathol."},{"key":"60019_CR65","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1073\/pnas.92.5.1555","volume":"92","author":"J Duyster","year":"1995","unstructured":"Duyster, J., Baskaran, R. & Wang, J. Y. Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc. Natl. Acad. Sci. USA 92, 1555\u20131559 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60019_CR66","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41375-019-0428-6","volume":"33","author":"TA Muller","year":"2019","unstructured":"Muller, T. A. et al. PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion. Leukemia 33, 1296\u20131301 (2019).","journal-title":"Leukemia"},{"key":"60019_CR67","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1084\/jem.20150556","volume":"213","author":"C Klein","year":"2016","unstructured":"Klein, C. et al. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. J. Exp. Med. 213, 273\u2013290 (2016).","journal-title":"J. Exp. Med."},{"key":"60019_CR68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.12384","volume":"1310","author":"C Schreck","year":"2014","unstructured":"Schreck, C., Bock, F., Grziwok, S., Oostendorp, R. A. & Istvanffy, R. Regulation of hematopoiesis by activators and inhibitors of Wnt signaling from the niche. Ann. N. Y. Acad. Sci. 1310, 32\u201343 (2014).","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60019-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T07:03:49Z","timestamp":1748070229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60019"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60019-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4833"}}